AstraZeneca AZN announced that the FDA has approved its blockbuster drug, Imfinzi (durvalumab), for a bladder cancer ...

Cambridge: AstraZeneca has announced that the Company's Imfinzi (durvalumab) in combination with chemotherapy has been ...

The US Food and Drug Administration (FDA) has approved AstraZeneca's human monoclonal antibody Imfinzi (durvalumab) with ...

AstraZeneca has secured another expansion of its Imfinzi for use in cancer patients before and after surgery. | Imfinzi is ...

UK pharma major AstraZeneca (LSE: AZN) today reported extended approvals in Europe for two of its cancer drugs: Imfinzi ...

AstraZenecas drug Imfinzi (NASDAQ: AZN) has received U.S. approval to treat adult patients with muscle-invasive bladder ...

AstraZeneca (AZ) has announced that its Imfinzi (durvalumab) perioperative regimen has been approved by the US Food and Drug ...

Imfinzi in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapy ...

Imfinzi in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapy ...

The Cambridge, England-based pharmaceuticals firm said Enhertu, or trastuzumab deruxtecan, has been approved in the EU as a therapy for adult patients with unresectable or metastatic hormone ...

Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone ...

Approval of Imfinzi marks the first and only perioperative immunotherapy indicated for muscle-invasive bladder cancer.